How can we do pharmacokinetic studies in the tropics?

被引:17
作者
Simpson, JA
Aarons, L
White, NJ
机构
[1] Univ Aberdeen, Dept Gen Practice & Primary Care, Foresterhill Hlth Ctr, Aberdeen AB25 2AY, Scotland
[2] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England
[3] Mahidol Univ, Fac Trop Med, Bangkok, Thailand
[4] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England
关键词
drugs; population pharmacokinetics; antimalarial agents; nonlinear mixed effects modelling; tropics;
D O I
10.1016/S0035-9203(01)90178-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Information regarding the pharmacokinetic (PK) and pharmacodynamic (PD) properties of a drug provides the basis for optimizing dosing. PK-PD information should be obtained from patients representative of the overall target population, but in many tropical hospitals or health care facilities it may be medically hazardous or logistically difficult for an ill patient or a young child to be sampled repeatedly. Traditional methods used to determine the pharmacokinetic properties of a drug require analysis of a large number of blood samples per subject. However, using modem statistical methods, sparse datasets (i.e. with assay results from only a few, or as little as one blood sample per subject) can now be analysed by a method termed 'the population approach'. Modern assay techniques can often be adapted to small blood volumes allowing finger prick blood samples to be taken. One of the major aims of the population approach is to distinguish and characterize patient and disease contributors to inter-individual variance in drug pharmacokinetics. The purpose of this paper is to explain the basis of the population approach, to highlight its advantages compared to traditional methods of analysis, and to review the application of the population approach to data from field studies of antimalarial drugs. The design of population pharmacokinetic studies is also discussed briefly. The principles discussed in the paper are also applicable to pharmacodynamic data.
引用
收藏
页码:347 / 351
页数:5
相关论文
共 29 条
[1]   Software for population pharmacokinetics and pharmacodynamics [J].
Aarons, L .
CLINICAL PHARMACOKINETICS, 1999, 36 (04) :255-264
[2]   Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies [J].
Aarons, L ;
Balant, LP ;
Mentre, F ;
Rowland, M ;
Steimer, JL ;
Vozeh, S .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 49 (04) :251-254
[3]   SPARSE DATA-ANALYSIS [J].
AARONS, L .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1993, 18 (01) :97-100
[4]  
AARONS L, 1992, INT J CLIN PHARM TH, V30, P520
[5]   Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients [J].
Alin, MH ;
Ashton, M ;
Kihamia, CM ;
Mtey, GJB ;
Bjorkman, A .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1996, 90 (01) :61-65
[6]   THE NONMEM SYSTEM [J].
BEAL, S ;
SHEINER, L .
AMERICAN STATISTICIAN, 1980, 34 (02) :118-119
[7]   DISTRIBUTION OF CHLOROQUINE AND ITS METABOLITE DESETHYL-CHLOROQUINE IN HUMAN-BLOOD CELLS AND ITS IMPLICATION FOR THE QUANTITATIVE-DETERMINATION OF THESE COMPOUNDS IN SERUM AND PLASMA [J].
BERGQVIST, Y ;
DOMEIJNYBERG, B .
JOURNAL OF CHROMATOGRAPHY, 1983, 272 (01) :137-148
[8]   Estimation of population pharmacokinetics using the Gibbs sampler [J].
Best, NG ;
Tan, KKC ;
Gilks, WR ;
Spiegelhalter, DJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1995, 23 (04) :407-435
[9]   OPTIMAL SAMPLING TIMES FOR PHARMACOKINETIC EXPERIMENTS [J].
DARGENIO, DZ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (06) :739-756
[10]  
Davidian M., 1995, NONLINEAR MODELS REP